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COVID-19 presents a global challenge. Advancements
in prevention and treatment are being developed to
counter this illness.[1, 2] The course of COVID-19
varies. People with comorbidities such as poorly controlled diabetes mellitus, severe pulmonary illnesses,
liver cirrhosis, and/or immunosuppressive states are at
greater risk of serious life-threatening complications.[3,
4] Treatment with corticosteroids has proven efficacious for patients with COVID-19 pneumonia and hypoxemia and diminishes the need for intubation.[5]
The emergence of rhino-orbital mucormycosis (ROCM)
has resulted from the prescribing of corticosteroids in
India. Diabetes mellitus is an independent, additional
risk factor. The triad of COVID-19, diabetes, and corticosteroid exposure seriously contributes to the pathogenesis of mucormycosis.[4]
Mucormycosis can also invade the lungs, skin, and
gastrointestinal tract, and/or be widely disseminated.
ROCM occurs following inhalation of fungal spores.[1]
The pathogenesis includes dysfunction of the immune
system. Vascular invasion is the hallmark of mucormycosis, characterized by thrombosis, infarction, and/or
necrosis. COVID-19 is associated with endothelial
damage, and thromboses serve as a nidus for fungal
invasion.[3, 4, 6] The involvement of CD+4, CD+8, and
T-lymphocytes and development of a cytokine storm

Received: December 3, 2021
Accepted: April 7, 2022

can result in free iron availability in some people.
Patients may present with fever, headache, nasal congestion/swelling, facial numbness, gingival eschars,
black palatal discoloration with possible perforation
of the nasal septum, and/or ocular proptosis, with
or without diplopia. The rapid dissemination of
mucormycosis characterizes the course, particularly
in diabetics. As the infection spreads, trigeminal
nerve palsies, obtundation, cavernous sinus thrombosis, and/or carotid artery involvement may occur.[7]
Intracranial involvement increases the fatality rate up
to 90%.[4]
Early diagnosis of ROCM is critical. Prompt treatment with amphotericin and itraconazole is recommended.[1] Surgical debridement is frequently indicated. Posaconazole, combination therapy with caspofungin, or both and iron-chelator therapies are being
investigated.[8]
Physicians need to be highly aware of the risk of mucormycosis in patients with COVID-19 treated with corticosteroids in the presence of illnesses associated with
immunosuppression. Prompt diagnosis of COVID-19,
managing predisposing factors such as diabetes mellitus, and when needed, judicious application of corticosteroids should help to mitigate the risk for mucormycosis.[8]
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